FIELD: medicine; pharmaceutics.
SUBSTANCE: preparation includs methylnaltrexone or its salt and a chelating agent. The preparation represents a solution which has pH from 2 to 6. The chelating agent is ethylenediaminetetraacetic acid or its derivative.
EFFECT: decomposing prevention of methylnaltrexone or its salts and stability of a methylnaltrexone preparation in the form of a solution after storage within 12 months.
10 cl, 3 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
| FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USING THEM | 2007 |
|
RU2539387C2 |
| PIPERACILLIN AND TAZOBACTAM-CONTAINING COMPOSITIONS USED FOR INJECTION | 2004 |
|
RU2322980C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2737264C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
| PREPARATIVE FORM OF ARGATROBAN | 2006 |
|
RU2416393C2 |
| MUCOADHESIVE COMPOSITION FOR TREATING STOMATOLOGICAL DISEASES AND METHOD FOR ITS OBTAINING | 2002 |
|
RU2242963C2 |
| ANTISEPTIC, INCLUDING MEGLUMINE OR ITS SALT | 2017 |
|
RU2745617C2 |
| COMPOSITION OF AQUEOUS SOLUTION OF RECOMBINANT HUMAN INTERFERON ALPHA-2 FOR RECTAL ADMINISTRATION | 2014 |
|
RU2564951C1 |
| PHARMACEUTICAL PRODUCTS CONTAINING BIPHOSPHONATES | 2004 |
|
RU2358739C2 |
